• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC.

作者信息

Killock David

机构信息

Nature Reviews Clinical Oncology, .

出版信息

Nat Rev Clin Oncol. 2025 Jan;22(1):1. doi: 10.1038/s41571-024-00974-z.

DOI:10.1038/s41571-024-00974-z
PMID:39592884
Abstract
摘要

相似文献

1
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC.一线治疗的早期转换可改善晚期胃/胃食管交界癌的治疗结果。
Nat Rev Clin Oncol. 2025 Jan;22(1):1. doi: 10.1038/s41571-024-00974-z.
2
A conceptual model for advanced/metastatic gastric or gastroesophageal junction cancer: a review of qualitative studies and results from patient interviews.晚期/转移性胃癌或胃食管交界癌的概念模型：定性研究综述及患者访谈结果
BMC Cancer. 2025 Jan 15;25(1):88. doi: 10.1186/s12885-025-13474-9.
3
A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.比较不可切除的晚期胃或胃食管连接部癌与食管腺癌患者一线治疗的真实世界治疗模式和临床结局。
Adv Ther. 2021 Jan;38(1):707-720. doi: 10.1007/s12325-020-01567-9. Epub 2020 Nov 26.
4
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.晚期食管癌、胃食管交界癌和胃腺癌的治疗与结局比较：一项基于人群的研究。
Ther Adv Med Oncol. 2023 Mar 21;15:17588359231162576. doi: 10.1177/17588359231162576. eCollection 2023.
5
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.检查点抑制剂治疗转移性胃癌的演进：现状与未来展望。
Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22.
6
Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.晚期/转移性胃癌或胃食管结合部癌患者在不同治疗线的真实世界治疗模式和临床结局。
Clin Colorectal Cancer. 2020 Mar;19(1):32-38.e3. doi: 10.1016/j.clcc.2019.09.001. Epub 2019 Sep 24.
7
Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?晚期胃癌或胃食管交界癌（GC/GEJC）治疗的新前沿：免疫疗法会成为未来的方向吗？
Front Oncol. 2020 Jul 21;10:912. doi: 10.3389/fonc.2020.00912. eCollection 2020.
8
Targeted literature review of the global burden of gastric cancer.全球胃癌负担的针对性文献综述。
Ecancermedicalscience. 2018 Nov 26;12:883. doi: 10.3332/ecancer.2018.883. eCollection 2018.
9
The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.PD-1/PD-L1抑制剂联合化疗作为不可切除的局部晚期HER2阴性胃癌或胃食管交界癌一线治疗的疗效和安全性：一项随机对照试验的荟萃分析
Front Immunol. 2025 Mar 26;16:1566939. doi: 10.3389/fimmu.2025.1566939. eCollection 2025.
10
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.替氟尿苷/替匹嘧啶在转移性胃食管结合部癌患者中的应用：来自 III 期 TAGS 研究的亚组分析。
Gastric Cancer. 2021 Jul;24(4):970-977. doi: 10.1007/s10120-021-01156-x. Epub 2021 Mar 13.

本文引用的文献

1
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.雷莫西尤单抗联合紫杉醇作为晚期HER2阴性胃癌或胃食管交界癌患者一线奥沙利铂化疗后的转换维持治疗与继续治疗的比较（ARMANI）：一项随机、开放标签、多中心3期试验
Lancet Oncol. 2024 Dec;25(12):1539-1550. doi: 10.1016/S1470-2045(24)00580-1. Epub 2024 Nov 15.